Cyril Berthet

Cyril Berthet

Auto-generated profile, based on publicly available information

Cyril Berthet

Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute-Frederick, Frederick, MD 21702, USA; Oncodesign, 20 Rue Jean Mazen, Dijon 21076, France

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2003 in Current Biology
Verified
Journal Article
Closed access
CBCyril Berthet
Cyril Berthet
EAEiman Aleem
Eiman Aleem
Vincenzo CoppolaVincenzo Coppola
Vincenzo Coppola
LTLino Tessarollo
Lino Tessarollo
PKPhilipp Kaldis
Philipp Kaldis

1 December 1996 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JRJean-Pierre Rouault
Jean-Pierre Rouault
NFNicole Falette
Nicole Falette
FGFabienne Guéhenneux
Fabienne Guéhenneux
CGCéline Guillot
Céline Guillot
RRRuth Rimokh
Ruth Rimokh
APAlain Puisieux
Alain Puisieux

30 September 2012 in Clinical Cancer Research
Verified
Journal Article
Closed access
SJSylvia Julien
Sylvia Julien
AMAna Merino-Trigo
Ana Merino-Trigo
LLLudovic Lacroix
Ludovic Lacroix
MPMarc Pocard
Marc Pocard
DGDiane Goéré
Diane Goéré
CBCyril Berthet
Cyril Berthet
Purpose: Patient-derived xenograft models are considered to represent the heterogeneity of human cancers and advanced preclinical models. Our consortium joins efforts to extensively develop and characterize a new collection of patient-derived colorectal cancer (CRC) models. Experimental Design: From the 85 unsupervised surgical colorectal samples collection, 54 tumors were successfully xenografted in immunodeficient mice and rats, representing 35 primary tumors, 5 peritoneal carcinoses and 14 metastases. Histologic and molecular characterization of patient tumors, first and late passages on mice includes the sequence of key genes involved in CRC (i.e., APC, KRAS, TP53), aCGH, and transcriptomic analysis. Results: This comprehensive characterization shows that our collection recapitulates the clinical situation about the histopathology and molecular diversity of CRC. Moreover, patient tumors and corresponding models are clustering together allowing comparison studies between clinical and preclinical data. Hence, we conducted pharmacologic monotherapy studies with standard of care for CRC (5-fluorouracil, oxaliplatin, irinotecan, and cetuximab). Through this extensive in vivo analysis, we have shown the loss of human stroma cells after engraftment, observed a metastatic phenotype in some models, and finally compared the molecular profile with the drug sensitivity of each tumor model. Through an experimental cetuximab phase II trial, we confirmed the key role of KRAS mutation in cetuximab resistance. Conclusions: This new collection could bring benefit to evaluate novel targeted therapeutic strategies and to better understand the basis for sensitivity or resistance of tumors from individual patients. Clin Cancer Res; 18(19); 5314–28. ©2012 AACR.

22 May 2001 in FEBS Letters
Verified
Journal Article
Closed access
SMSatoru Matsuda
Satoru Matsuda
JRJean-Pierre Rouault
Jean-Pierre Rouault
JMJean-Pierre Magaud
Jean-Pierre Magaud
CBCyril Berthet
Cyril Berthet

1 May 2006 in Developmental Cell
Verified
Journal Article
Closed access
CBCyril Berthet
Cyril Berthet
KKKimberly D. Klarmann
Kimberly D. Klarmann
MHMary Beth Hilton
Mary Beth Hilton
HSHyung Chan Suh
Hyung Chan Suh
JKJonathan R. Keller
Jonathan R. Keller
PKPhilipp Kaldis
Philipp Kaldis

1 September 2007 in Molecular Endocrinology
Verified
Journal Article
Open access
PDF file
SRSingareddy Rajareddy
Singareddy Rajareddy
PRPradeep Reddy
Pradeep Reddy
CDChun Du
Chun Du
LLLian Liu
Lian Liu
KJKrishna Jagarlamudi
Krishna Jagarlamudi
KLKui Liu
Kui Liu
In humans, the molecular mechanisms underlying ovarian follicle endowment and activation, which are closely related to the control of female reproduction, occurrence of menopause, and related diseases such as premature ovarian failure, are poorly understood. In the current study, we provide several lines of genetic evidence that the cyclin-dependent kinase (Cdk) inhibitor 1B (commonly known as p27kip1 or p27) controls ovarian development in mice by suppressing follicle endowment and activation, and by promoting follicle death. In p27-deficient (p27−/−) mice, postnatal follicle assembly was accelerated, and the number of endowed follicles was doubled as compared with p27+/+ mice. Moreover, in p27−/− ovaries the primordial follicle pool was prematurely activated once it was endowed, and at the same time the massive follicular death that occurs before sexual maturity was rescued by loss of p27. In early adulthood, however, the overactivated follicular pool in p27−/− ovaries was largely depleted, causing premature ovarian failure. Furthermore, we have extensively studied the molecular mechanisms underlying the above-mentioned phenotypes seen in p27−/− ovaries and have found that p27 controls follicular development by several distinct mechanisms at different stages of development of the ovary. For example, p27 controls oocyte growth by suppressing the functions of Cdk2/Cdc2-cyclin A/E1 in oocytes that are arrested at the diplotene stage of meiosis I. This function of p27 is distinct from its well-known role as a suppressor of cell cycle progression. In addition, we have found that p27 activates the caspase-9-caspase-3-caspase-7-poly (ADP-ribose) polymeraseapoptotic cascade by inhibiting Cdk2/Cdc2-cyclin A/B1 kinase activities in follicles, thereby inducing follicle atresia. Our results suggest that the p27 gene is important in determining mammalian ovarian development. This study therefore provides insight into ovary-borne genetic aberrations that cause defects in folliculogenesis and infertility in humans.